Resof-l

Resof-l

Prescription requiredRx Required

Salt Composition: Sofosbuvir and Ledipasvir

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

28 tablet

About The Product

Hepatitis C

Resof-L Tablet is an antiviral medication, which is used in combination with other medicines. It is used in the treatment of chronic hepatitis C virus (HCV) infection. It stops or prevents the growth of viruses in the body and helps remove the virus from the blood. Resof-L Tablet helps you to recover faster and control the infection from spreading in your body. This is a prescription-based medicine, which is to be taken only when prescribed by your doctor.


Uses

Treatment of Chronic hepatitis C virus (HCV) infection

Side Effects

  • The human body reacts differently to Resof-L Tablet.
  • Response or undesired symptoms vary from individual to individual.
  • Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention.
  • Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.
  • Some of the common side effects of Resof-L Tablet are mentioned below: Headache Fever Chills Nausea Insomnia (difficulty in sleeping)
  • Tiredness Loss of appetite Fatigue Anemia (low number of red blood cells)
  • Skin rash

How To Use

  • Take the dose of Resof-L Tablet as per your healthcare provider’s prescription.
  • Do not stop taking the medicine suddenly, unless your doctor tells you.
  • This medicine is given under the strict supervision of a doctor.
  • Do not self-administer.
  • Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.
  • Resof-L Tablet can be taken without food or with food.
  • The doctor will provide emergency medical treatment.
  • You should not break, crush, or chew the medicine; it should be swallowed as a whole.
  • It is advised to eat a healthy diet and drink plenty of fluids to overcome and prevent the side effects that have occurred after taking ​Resof-L Tablet.

How It Works

Resof-L Tablet is an antiviral medicine made up of Sofosbuvir and Ledipasvir. Both ingredients present in the medicine prevent the virus from multiplying.

Thus, the viral count in the blood gets lowered, and the infection can be eliminated from the body. This medication is suitable for use in both adults and children aged three years and above.

Resof-L Tablet inhibits an important Nonstructural protein 5A (NS5A) and viral phosphoprotein, which are involved in replication of the virus, assembly, secretion, and RNA viral production.

Safety Advice

Alcohol
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Resof-L Tablet. Consult your doctor for further information.
Pregnancy
Resof-L Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking Resof-L Tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
Resof-L Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking Resof-L Tablet while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
It is advisable not to drive or operate heavy machinery after taking Resof-L Tablet, as you may feel dizzy.
Kidney
Share your medical history with your healthcare expert in case of kidney disease before taking Resof-L Tablet. Patients with renal impairment must be careful while taking Resof-L Tablet. They may require adjustment in the dose.
Liver
Inform your doctor before starting Resof-L Tablet if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking Resof-L Tablet. They may require adjustment in the dose.

FAQs

Resof-L Tablet ​is an antiviral medication, used along with other medications, in the treatment of chronic Hepatitis C Virus (HCV) infection in adults.

Reference

Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. (2023). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 16(4):459-64.


Duc N. T, Vittorio F, Alexander Z, Venkat R. G, Akihiro H, Mingjun H, Jason A. W. (2025). The Discovery and Chemical Development of Odalasvir, a Potent and Selective HCV NS5A Inhibitor, Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5, 1-58.


Lele Z, Matthew H, Prahalad G, Mahan G, Steven K, Haiting C, Paul K, Eleanor B, M. Azim A, Katrina L, Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure, PLOS Pathogens, 21, 4, (e1012959).


Nambaru Vidya Sagar, Anamika Goyal, Abhishek Raj, Subhash Chandra, Upendra Nath Gupta, Prabhat Agrawal, Rajat Gupta, Rahul Agrahari. (2024). SVR timelines in hepatitis irrespective of viral genotype: An Indian perspective, Journal of Family Medicine and Primary Care, 14, 4, 1425-1430.


Preferred Therapy for Specific Viral Pathogens, Nelson’s Pediatric Antimicrobial Therapy, (2025).


Thomas R. O, David J. W, Varun S, Kerry G.M., Sabrina C, Francine S.B., Ludmila P. O, Ruth M. P, Jennifer B. L. (2024). IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C, Journal of Infection, 89, 5, (106258).


Yong P, Sitthichai K, Nungruthai S, Pornjarim N, Ritthideach Y, Wijittra P, Napaporn P, Chatree J. (2025). Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions, Journal of Clinical Medicine, 14, 11, 3946.


i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026